{"schema_version":"secwatch.filing_event.v1","accession":"0001746473-23-000072","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.296654+00:00","generated_at":"2026-06-08T07:10:00.114183+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pliant Therapeutics reports Q3 net loss of $41.5M; positive bexotegrast PSC interim data","bullets":["Net loss of $41.5M vs $30.6M in prior-year quarter; R&D expense $32.3M, G&A $15.3M.","Cash, cash equivalents and short-term investments of $523.6M, funding operations into H2 2026.","Positive 12-week data from Phase 2a INTEGRIS-PSC trial; 160 mg dose showed statistically significant reduction in ELF and PRO-C3 vs placebo.","DSMB recommended INTEGRIS-PSC continue without modification; 320 mg data expected Q1 2024.","Appointed Minnie Kuo as Chief Development Officer and Mishima Gerhart as Chief Regulatory Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001746473-23-000072","json":"https://secwatch.observer/filing/0001746473-23-000072.json","markdown":"https://secwatch.observer/filing/0001746473-23-000072.md","text":"https://secwatch.observer/filing/0001746473-23-000072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000174647323000072/0001746473-23-000072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000174647323000072/plrx-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:10:00.114183+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b724824574d6c3f59e4df5634038242896a2e824","claim":"PLIANT THERAPEUTICS, INC. reported financial results for third quarter ended September 30, 2023.","evidence_excerpt":"On November 9, 2023, Pliant Therapeutics, Inc. (the \"Company\") issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647323000072/0001746473-23-000072-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}